Efficacy and Safety of Novel Continuous Subcutaneous Levodopa Infusion Therapies ND0612 and ABBV-951 for Parkinson's Disease: A Systematic Review.

IF 2.9 4区医学 Q2 CLINICAL NEUROLOGY

Journal of Geriatric Psychiatry and Neurology Pub Date : 2025-04-20 DOI:10.1177/08919887251335011

Matheus de Medeiros Fernandes, Luis Otávio Souza Nogueira, Isabella Soares Marques Rabelo, Louise Dalla Corte Dallé, Angela Maria Sandini Corso, Fernanda Medeiros Santos, Roberta Arb Saba Rodrigues Pinto, Vanderci Borges, Henrique Ballalai Ferraz, Dayany Leonel Boone

{"title":"Efficacy and Safety of Novel Continuous Subcutaneous Levodopa Infusion Therapies ND0612 and ABBV-951 for Parkinson's Disease: A Systematic Review.","authors":"Matheus de Medeiros Fernandes, Luis Otávio Souza Nogueira, Isabella Soares Marques Rabelo, Louise Dalla Corte Dallé, Angela Maria Sandini Corso, Fernanda Medeiros Santos, Roberta Arb Saba Rodrigues Pinto, Vanderci Borges, Henrique Ballalai Ferraz, Dayany Leonel Boone","doi":"10.1177/08919887251335011","DOIUrl":null,"url":null,"abstract":"<p><p>IntroductionRecent research in Parkinson's disease (PD) has highlighted the potential therapies of continuous subcutaneous infusions (CSCI) of levodopa/carbidopa (ND0612) and foslevodopa/foscarbidopa (ABBV-951). This systematic review aims to explore their effectiveness and safety for PD.MethodsGuided by the PRISMA statement, we systematically searched 3 electronic databases: MEDLINE, Embase, and Cochrane Central. We combined quantitative and qualitative data for synthesis and descriptive analysis. Quality assessment and risk of bias were evaluated by ROBINS-1 and Rob-2 criteria.ResultsWe included 6 records with a total of 698 patients. CSCI therapies reduced motor symptoms in PD patients with levodopa-related motor fluctuations and clinical improvements. Infusions-site reactions were the main adverse event recorded.ConclusionsND0612 and ABBV-951 are promising options for enhancing motor control and quality of life in PD patients. However, further research is needed to assess long-term efficacy, safety, and comparisons with oral levodopa and device-aided treatments.</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"8919887251335011"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Geriatric Psychiatry and Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08919887251335011","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

IntroductionRecent research in Parkinson's disease (PD) has highlighted the potential therapies of continuous subcutaneous infusions (CSCI) of levodopa/carbidopa (ND0612) and foslevodopa/foscarbidopa (ABBV-951). This systematic review aims to explore their effectiveness and safety for PD.MethodsGuided by the PRISMA statement, we systematically searched 3 electronic databases: MEDLINE, Embase, and Cochrane Central. We combined quantitative and qualitative data for synthesis and descriptive analysis. Quality assessment and risk of bias were evaluated by ROBINS-1 and Rob-2 criteria.ResultsWe included 6 records with a total of 698 patients. CSCI therapies reduced motor symptoms in PD patients with levodopa-related motor fluctuations and clinical improvements. Infusions-site reactions were the main adverse event recorded.ConclusionsND0612 and ABBV-951 are promising options for enhancing motor control and quality of life in PD patients. However, further research is needed to assess long-term efficacy, safety, and comparisons with oral levodopa and device-aided treatments.

查看原文本刊更多论文

新型左旋多巴持续皮下输注疗法ND0612和ABBV-951治疗帕金森病的疗效和安全性：系统评价

最近对帕金森病（PD）的研究强调了左旋多巴/卡比多巴（ND0612）和左旋多巴/卡比多巴（ABBV-951）持续皮下输注（CSCI）的潜在治疗方法。本系统综述旨在探讨其治疗帕金森病的有效性和安全性。方法以PRISMA声明为指导，系统检索MEDLINE、Embase、Cochrane Central 3个电子数据库。我们将定量和定性数据结合起来进行综合和描述性分析。采用ROBINS-1和robins -2标准评价质量评价和偏倚风险。结果纳入6条记录，共698例患者。CSCI治疗可减轻PD患者的运动症状，伴有左旋多巴相关的运动波动和临床改善。输液部位反应是记录的主要不良事件。结论snd0612和ABBV-951是改善PD患者运动控制和生活质量的有希望的选择。然而，需要进一步的研究来评估长期疗效、安全性，并与口服左旋多巴和器械辅助治疗进行比较。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Geriatric Psychiatry and Neurology 医学-精神病学

CiteScore

6.20

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Geriatric Psychiatry and Neurology (JGP) brings together original research, clinical reviews, and timely case reports on neuropsychiatric care of aging patients, including age-related biologic, neurologic, and psychiatric illnesses; psychosocial problems; forensic issues; and family care. The journal offers the latest peer-reviewed information on cognitive, mood, anxiety, addictive, and sleep disorders in older patients, as well as tested diagnostic tools and therapies.